Federal Register / Vol. 75, No. 178 / Wednesday, September 15, 2010 / Notices 56137 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–343P] 

Controlled Substances: Proposed 

Aggregate Production Quotas for 2011 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of proposed year 2011 

aggregate production quotas. 

SUMMARY: This notice proposes initial 

year 2011 aggregate production quotas 

for controlled substances in schedules I 

and II of the Controlled Substances Act 

(CSA). 

DATES: Written comments must be 

postmarked and electronic comments 

must be submitted on or before October 

15, 2010. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–343P’’ on all written and 

electronic correspondence. Written 

comments sent via regular or express 

mail should be sent to the Drug 

Enforcement Administration, Attention: 

DEA Federal Register Representative/ 

ODL, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

may be sent to DEA by sending an 

electronic message to 

dea.diversion.policy@usdoj.gov. DEA 

will accept attachments to electronic 

comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here. 

Please note that DEA is requesting 

that electronic comments be submitted 

before midnight Eastern Time on the 

day the comment period closes. 

Commenters in time zones other than 

Eastern Time may want to consider this 

so that their electronic comments are 

received timely. All comments sent via 

regular or express mail will be 

considered timely if postmarked on the 

day the comment period closes. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, PhD, Chief, Drug 

and Chemical Evaluation Section, 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 307–7183. 

Availability Of Public Comments: 

Please note that all comments received 

are considered part of the public record 

and made available for public 

inspection in the Drug Enforcement 

Administration’s public docket. Such 

information includes personal 

identifying information (such as your 

name, address, etc.) voluntarily 

submitted by the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be made 

available in the public docket, you must 

include the phrase ‘‘PERSONAL 

IDENTIFYING INFORMATION’’ in the 

first paragraph of your comment. You 

must also place all the personal 

identifying information you do not want 

made available in the public docket in 

the first paragraph of your comment and 

identify what information you want 

redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it made 

available in the public docket, you must 

include the phrase ‘‘CONFIDENTIAL 

BUSINESS INFORMATION’’ in the first 

paragraph of your comment. You must 

also prominently identify confidential 

business information to be redacted 

within the comment. 

If a comment has so much 

confidential business information that it 

cannot be effectively redacted, all or 

part of that comment may not be made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted and the comment, in 

redacted form, will be placed in the 

Drug Enforcement Administration’s 

public docket file. Please note that the 

Freedom of Information Act applies to 

all comments received. If you wish to 

inspect the agency’s public docket file 

in person by appointment, please see 

the FOR FURTHER INFORMATION paragraph. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The proposed year 2011 aggregate 

production quotas represent those 

quantities of controlled substances that 

may be produced in the United States in 

2011 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research, and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the year 2011 

aggregate production quotas, the Deputy 

Administrator considered the following 

factors: total actual 2009 and estimated 

2010 and 2011 net disposals of each 

substance by all manufacturers; 

estimates of 2010 year-end inventories 

of each substance and of any substance 

manufactured from it and trends in 

accumulation of such inventories; 

product development requirements of 

both bulk and finished dosage form 

manufacturers; projected demand as 

indicated by procurement quota 

applications filed pursuant to 21 CFR 

1303.12; and other pertinent 

information. 

Pursuant to 21 CFR 1303, the Deputy 

Administrator of the DEA will adjust the 

2011 aggregate production quotas and 

individual manufacturing quotas 

allocated for the year based upon 2010 

year-end inventory and actual 2010 

disposition data supplied by quota 

recipients for each basic class of 

schedules I or II controlled substances. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA of 1970 (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by 28 CFR 0.100, and redelegated 

to the Deputy Administrator pursuant to 

28 CFR 0.104, the Deputy Administrator 

hereby proposes that the year 2011 

aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic Class—Schedule I 

Proposed 

2011 

quotas 

(g) 

1-Methyl-4-phenyl-4-propionoxypiperidine ........................................................................................................................................... 2 

2,5-Dimethoxyamphetamine ................................................................................................................................................................ 2 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ...................................................................................................................................... 2 

2,5-Dimethoxy-4-n-propylthiophenethylamine ..................................................................................................................................... 2 

3-Methylfentanyl ................................................................................................................................................................................... 2 

3-Methylthiofentanyl ............................................................................................................................................................................. 2 


srobinson on DSKHWCL6B1PROD with NOTICES
56138 Federal Register / Vol. 75, No. 178 / Wednesday, September 15, 2010 / Notices 

Basic Class—Schedule I 

Proposed 

2011 

quotas 

(g) 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................ 20 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ............................................................................................................................. 10 

3,4-Methylenedioxymethamphetamine (MDMA) ................................................................................................................................. 20 

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 2 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ...................................................................................................................................... 2 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .................................................................................................................................. 2 

4-Methoxyamphetamine ...................................................................................................................................................................... 77 

4-Methylaminorex ................................................................................................................................................................................ 2 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ...................................................................................................................................... 2 

5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 2 

5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 2 

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 2 

Acetyldihydrocodeine ........................................................................................................................................................................... 2 

Acetylmethadol .................................................................................................................................................................................... 2 

Allylprodine .......................................................................................................................................................................................... 2 

Alphacetylmethadol .............................................................................................................................................................................. 2 

Alpha-ethyltryptamine .......................................................................................................................................................................... 2 

Alphameprodine ................................................................................................................................................................................... 2 

Alphamethadol ..................................................................................................................................................................................... 2 

Alpha-methylfentanyl ........................................................................................................................................................................... 2 

Alpha-methylthiofentanyl ...................................................................................................................................................................... 2 

Alpha-methyltryptamine (AMT) ............................................................................................................................................................ 2 

Aminorex .............................................................................................................................................................................................. 2 

Benzylmorphine ................................................................................................................................................................................... 2 

Betacetylmethadol ............................................................................................................................................................................... 2 

Beta-hydroxy-3-methylfentanyl ............................................................................................................................................................ 2 

Beta-hydroxyfentanyl ........................................................................................................................................................................... 2 

Betameprodine ..................................................................................................................................................................................... 2 

Betamethadol ....................................................................................................................................................................................... 2 

Betaprodine .......................................................................................................................................................................................... 2 

Bufotenine ............................................................................................................................................................................................ 3 

Cathinone ............................................................................................................................................................................................. 3 

Codeine-N-oxide .................................................................................................................................................................................. 602 

Diethyltryptamine ................................................................................................................................................................................. 2 

Difenoxin .............................................................................................................................................................................................. 3,000 

Dihydromorphine .................................................................................................................................................................................. 3,608,000 

Dimethyltryptamine .............................................................................................................................................................................. 3 

Gamma-hydroxybutyric acid ................................................................................................................................................................ 3,000,000 

Heroin .................................................................................................................................................................................................. 20 

Hydromorphinol .................................................................................................................................................................................... 2 

Hydroxypethidine ................................................................................................................................................................................. 2 

Ibogaine ............................................................................................................................................................................................... 1 

Lysergic acid diethylamide (LSD) ........................................................................................................................................................ 15 

Marihuana ............................................................................................................................................................................................ 21,000 

Mescaline ............................................................................................................................................................................................. 5 

Methaqualone ...................................................................................................................................................................................... 7 

Methcathinone ..................................................................................................................................................................................... 4 

Methyldihydromorphine ........................................................................................................................................................................ 2 

Morphine-N-oxide ................................................................................................................................................................................ 605 

N-Benzylpiperazine .............................................................................................................................................................................. 2 

N,N-Dimethylamphetamine .................................................................................................................................................................. 2 

N-Ethylamphetamine ........................................................................................................................................................................... 2 

N-Hydroxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 2 

Noracymethadol ................................................................................................................................................................................... 2 

Norlevorphanol ..................................................................................................................................................................................... 52 

Normethadone ..................................................................................................................................................................................... 2 

Normorphine ........................................................................................................................................................................................ 16 

Para-fluorofentanyl ............................................................................................................................................................................... 2 

Phenomorphan .................................................................................................................................................................................... 2 

Pholcodine ........................................................................................................................................................................................... 2 

Psilocybin ............................................................................................................................................................................................. 2 

Psilocyn ................................................................................................................................................................................................ 2 

Tetrahydrocannabinols ........................................................................................................................................................................ 264,000 

Thiofentanyl ......................................................................................................................................................................................... 2 

Tilidine .................................................................................................................................................................................................. 10 

Trimeperidine ....................................................................................................................................................................................... 2 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 178 / Wednesday, September 15, 2010 / Notices 56139 

Basic Class—Schedule II 

Proposed 

2011 

quotas 

(g) 

1-Phenylcyclohexylamine .................................................................................................................................................................... 2 

1-piperdinocyclohexanecarbonitrile ..................................................................................................................................................... 2 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................................... 2,500,000 

Alfentanil .............................................................................................................................................................................................. 8,000 

Alphaprodine ........................................................................................................................................................................................ 2 

Amobarbital .......................................................................................................................................................................................... 40,003 

Amphetamine (for conversion) ............................................................................................................................................................ 7,500,000 

Amphetamine (for sale) ....................................................................................................................................................................... 18,600,000 

Cocaine ................................................................................................................................................................................................ 247,000 

Codeine (for conversion) ..................................................................................................................................................................... 65,000,000 

Codeine (for sale) ................................................................................................................................................................................ 39,605,000 

Dextropropoxyphene ............................................................................................................................................................................ 92,000,000 

Dihydrocodeine .................................................................................................................................................................................... 800,000 

Diphenoxylate ...................................................................................................................................................................................... 827,000 

Ecgonine .............................................................................................................................................................................................. 83,000 

Ethylmorphine ...................................................................................................................................................................................... 2 

Fentanyl ............................................................................................................................................................................................... 1,428,000 

Glutethimide ......................................................................................................................................................................................... 2 

Hydrocodone (for sale) ........................................................................................................................................................................ 55,000,000 

Hydromorphone ................................................................................................................................................................................... 3,455,000 

Isomethadone ...................................................................................................................................................................................... 11 

Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................ 3 

Levomethorphan .................................................................................................................................................................................. 5 

Levorphanol ......................................................................................................................................................................................... 10,000 

Lisdexamfetamine ................................................................................................................................................................................ 9,000,000 

Meperidine ........................................................................................................................................................................................... 6,600,000 

Meperidine Intermediate-A .................................................................................................................................................................. 3 

Meperidine Intermediate-B .................................................................................................................................................................. 7 

Meperidine Intermediate-C .................................................................................................................................................................. 3 

Metazocine ........................................................................................................................................................................................... 1 

Methadone (for sale) ........................................................................................................................................................................... 20,000,000 

Methadone Intermediate ...................................................................................................................................................................... 26,000,000 

Methamphetamine ............................................................................................................................................................................... 3,130,000 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, 

non-prescription product; 2,331,000 grams for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ................................................................................................................................................................................... 50,000,000 

Morphine (for conversion) .................................................................................................................................................................... 83,000,000 

Morphine (for sale) .............................................................................................................................................................................. 39,000,000 

Nabilone ............................................................................................................................................................................................... 9,002 

Noroxymorphone (for conversion) ....................................................................................................................................................... 9,000,000 

Noroxymorphone (for sale) .................................................................................................................................................................. 41,000 

Opium (powder) ................................................................................................................................................................................... 230,000 

Opium (tincture) ................................................................................................................................................................................... 1,500,000 

Oripavine .............................................................................................................................................................................................. 15,000,000 

Oxycodone (for conversion) ................................................................................................................................................................ 5,600,000 

Oxycodone (for sale) ........................................................................................................................................................................... 105,500,000 

Oxymorphone (for conversion) ............................................................................................................................................................ 12,800,000 

Oxymorphone (for sale) ....................................................................................................................................................................... 3,070,000 

Pentobarbital ........................................................................................................................................................................................ 28,000,000 

Phenazocine ........................................................................................................................................................................................ 1 

Phencyclidine ....................................................................................................................................................................................... 14 

Phenmetrazine ..................................................................................................................................................................................... 2 

Phenylacetone ..................................................................................................................................................................................... 8,000,000 

Racemethorphan ................................................................................................................................................................................. 2 

Remifentanil ......................................................................................................................................................................................... 2,500 

Secobarbital ......................................................................................................................................................................................... 67,000 

Sufentanil ............................................................................................................................................................................................. 7,000 

Tapentadol ........................................................................................................................................................................................... 1,000,000 

Thebaine .............................................................................................................................................................................................. 126,000,000 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 be established 

at zero. 

All interested persons are invited to 

submit their comments in writing or 

electronically regarding this proposal 

following the procedures in the 

ADDRESSES section of this document. A 

person may object to or comment on the 

proposal relating to any of the abovementioned substances without filing 


srobinson on DSKHWCL6B1PROD with NOTICES
56140 Federal Register / Vol. 75, No. 178 / Wednesday, September 15, 2010 / Notices 

comments or objections regarding the 

others. If a person believes that one or 

more of these issues warrant a hearing, 

the individual should so state and 

summarize the reasons for this belief. 

In the event that comments or 

objections to this proposal raise one or 

more issues which the Deputy 

Administrator finds warrant a hearing, 

the Deputy Administrator shall order a 

public hearing by notice in the Federal 

Register, summarizing the issues to be 

heard and setting the time for the 

hearing. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $129,400,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: September 3, 2010. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. 2010–22905 Filed 9–14–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Office of Justice Programs 

[OJP (BJA) Docket No. 1531] 

Meeting of the Department of Justice’s 

(DOJ’s) National Motor Vehicle Title 

Information System (NMVTIS) Federal 

Advisory Committee 

AGENCY: Office of Justice Programs 

(OJP), Justice. 

ACTION: Notice of meeting. 

SUMMARY: This is an announcement of a 

meeting of DOJ’s National Motor 

Vehicle Title Information System 

(NMVTIS) Federal Advisory Committee 

to discuss the role of the NMVTIS 

Federal Advisory Committee Members 

and various issues relating to the 

operation and implementation of 

NMVTIS. 

DATES: The meeting will take place on 

Thursday, October 7th, 2010 from 8:30 

a.m. to 4 p.m. ET and on Friday, 

October 8th, 2010 from 8:30 a.m. to 12 

p.m. ET. 

ADDRESSES: The meeting will take place 

at the Omni Shoreham Hotel, 2500 

Calvert Street, NW., Washington, DC 

20008; Phone: (202) 234–0700. 

FOR FURTHER INFORMATION CONTACT: 

Alissa Huntoon, Designated Federal 

Employee (DFE), Bureau of Justice 

Assistance, Office of Justice Programs, 

810 7th Street Northwest, Washington, 

DC 20531; Phone: (202) 305–1661 [note: 

this is not a toll-free number]; E-mail: 

Alissa.Huntoon@usdoj.gov. 

SUPPLEMENTARY INFORMATION: This 

meeting is open to the public. Members 

of the public who wish to attend this 

meeting must register with Ms. Alissa 

Huntoon at the above address at least 

seven (7) days in advance of the 

meeting. Registrations will be accepted 

on a space available basis. Access to the 

meeting will not be allowed without 

registration. Please bring photo 

identification and allow extra time prior 

to the meeting. Interested persons 

whose registrations have been accepted 

may be permitted to participate in the 

discussions at the discretion of the 

meeting chairman and with approval of 

the DFE. 

Anyone requiring special 

accommodations should notify Ms. 

Huntoon at least seven (7) days in 

advance of the meeting. 

Purpose 

The NMVTIS Federal Advisory 

Committee will provide input and 

recommendations to the Office of Justice 

Programs (OJP) regarding the operations 

and administration of NMVTIS. The 

primary duties of the NMVTIS Federal 

Advisory Committee will be to advise 

the Bureau of Justice Assistance (BJA) 

Director on NMVTIS-related issues, 

including but not limited to: 

Implementation of a system that is selfsustainable with user fees; options for 

alternative revenue-generating 

opportunities; determining ways to 

enhance the technological capabilities 

of the system to increase its flexibility; 

and options for reducing the economic 

burden on current and future reporting 

entities and users of the system. 

Alissa Huntoon, 

NMVTIS DFE, Bureau of Justice Assistance, 

Office of Justice Programs. 

[FR Doc. 2010–22917 Filed 9–14–10; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF LABOR 

Employment and Training 

Administration 

Comment Request for Information 

Collection for the YouthBuild (YB) 

Reporting System (OMB Control No. 

1205–0464), Extension Without 

Revisions 

AGENCY: Employment and Training 

Administration. 

ACTION: Notice. 

SUMMARY: The Department of Labor, as 

part of its continuing effort to reduce 

paperwork and respondent burden 

conducts a preclearance consultation 

program to provide the general public 

and federal agencies with an 

opportunity to comment on proposed 

and/or continuing collections of 

information in accordance with the 

Paperwork Reduction Act of 1995 

(PRA95) [44 U.S.C. 3506(c)(2)(A)]. This 

program helps to ensure that requested 

data can be provided in the desired 

format, reporting burden (time and 

financial resources) is minimized, 


srobinson on DSKHWCL6B1PROD with NOTICES